Definition

A preparation of human T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20 and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/anti-CD20/anti-CD22 CAR T cells LCAR-AIO target and bind to CD19, CD20 and CD22 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.